Retension Pharmaceuticals, Inc. RTSN
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.94% | 74.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.64% | 46.59% | |||
| Operating Income | -22.64% | -46.59% | |||
| Income Before Tax | -24.33% | -51.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -24.33% | -51.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.33% | -51.94% | |||
| EBIT | -22.64% | -46.59% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -24.17% | -51.69% | |||
| Normalized Basic EPS | -24.18% | -51.69% | |||
| EPS Diluted | -24.17% | -51.69% | |||
| Normalized Diluted EPS | -24.18% | -51.69% | |||
| Average Basic Shares Outstanding | 0.12% | 0.16% | |||
| Average Diluted Shares Outstanding | 0.12% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||